	US 11,931,404 B2
	Use of ultrarapid acting insulin
Anders Hasager Boss, Princeton, NJ (US); and Richard Petrucci, New Canaan, CT (US)
Assigned to MannKind Corporation, Danbury, CT (US)
Filed by MannKind Corporation, Westlake Village, CA (US)
Filed on Apr. 26, 2021, as Appl. No. 17/240,802.
Application 17/240,802 is a continuation of application No. 16/385,915, filed on Apr. 16, 2019, granted, now 11,013,788.
Application 16/385,915 is a continuation of application No. 15/300,239, granted, now 10,307,464, issued on Jun. 4, 2019, previously published as PCT/US2015/022956, filed on Mar. 27, 2015.
Claims priority of provisional application 61/972,159, filed on Mar. 28, 2014.
Prior Publication US 2021/0244800 A1, Aug. 12, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/28 (2006.01); A61K 9/00 (2006.01); A61K 31/155 (2006.01)

CPC A61K 38/28 (2013.01) [A61K 9/007 (2013.01); A61K 9/0075 (2013.01); A61K 31/155 (2013.01); A61K 9/0019 (2013.01)]

19 Claims

1. A method of treating diabetes comprising treating a subject who is monitored for pre-meal blood glucose levels for 10 days and regularly has a pre-meal blood glucose level greater than 100 mg/dL comprising:

administering by inhalation an initial dose taken at mealtime and a second dose of between 10% to 100% of said initial dose taken 30 to 150 minutes after beginning the meal; wherein the pre-meal blood glucose of the subject for a next meal is regularly greater than 140 mg/dL.